<div id="readability-page-1"><div><p><span>Brynjelsen Sean Chief Executive Officer of Eton Pharmaceuticals Inc [ETON] filed a Form 4 on December 12, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:</span></p><div><table><tbody><tr><td><span>Date</span></td><td><span>12/12/25</span></td></tr><tr><td><span>Transaction</span></td><td><span>Surrender(1)</span></td></tr><tr><td><span>Shares</span></td><td><span>6,732</span></td></tr><tr><td><span>Price</span></td><td><span>$16.83</span></td></tr><tr><td><span>Value</span></td><td><span>$113,300</span></td></tr></tbody></table></div><p><span>Ending Holdings: 2,894,281 - Direct</span></p><ul><li><span>(1)</span></li><li><span>Surrender of shares back to company to pay option exercise cost and/or resulting tax liability.</span></li></ul><p><span>For a free trial, or to learn more about our insider trading analysis and data services, please visit http://www.washingtonservice.com or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.</span></p><p><span>Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.</span></p><span> </span></div></div>

ETON

<p>Eton Pharmaceuticals CEO Sean Brynjelsen surrendered 6,732 shares back to the company to cover option exercise costs and tax liabilities, as disclosed in a Form 4 filed with the SEC on December 12, 2025. The shares were valued at $113,300, with an ending direct holding of 2,894,281 shares.</p>

CEO Brynjelsen Surrenders 6,732 Of Eton Pharmaceuticals Inc [ETON]